Daijiworld Media Network- Copenhagen

Copenhagen, Sep 10: Danish pharmaceutical giant Novo Nordisk A/S, the maker of blockbuster diabetes and weight-loss drug Ozempic, has announced plans to slash 9,000 jobs worldwide as part of a sweeping transformation strategy.

The company, which has already issued two downward revisions this year, made its third cut to profit forecasts, citing the need to recover from a steep slump in performance.

In its fresh guidance, Novo projected operating profit growth of 4% to 10% at constant exchange rates, a sharp downgrade from its February forecast of up to 27% growth.

The layoffs, aimed at saving DKK 8 billion ($1.3 billion) by 2026, will significantly affect Denmark, where around 5,000 positions are set to be cut, the company said.

In a statement, Novo Nordisk explained that the restructuring is intended to simplify the organisation, improve decision-making speed, and redirect resources toward high-potential growth areas such as diabetes and obesity care.

The move marks one of the most aggressive reorganisations in the company’s history, underscoring the mounting pressures in the global pharmaceutical sector despite the runaway success of Ozempic.